PMV Pharmaceuticals, Inc., known as PMV Pharma and listed on Nasdaq under PMVP, priced an underwritten public offering comprising 22.055 million common shares and pre-funded warrants for up to 19.9 million shares, along with warrants to purchase 41.955 million common shares. The accompanying warrants will carry an initial exercise price of $1.21 per share, are immediately exercisable and expire five years after issuance, subject to adjustment following a specified regulatory milestone. Gross proceeds are expected to be approximately $50.8 million before underwriting discounts, commissions, offering expenses and any warrant exercises. The offering is expected to close on or about Sept. 2, 2026, subject to customary closing conditions, with TD Cowen acting as sole book-running manager. PMV Pharma develops small-molecule therapies targeting p53, and says TP53 mutations occur in approximately half of all cancers.